Supplement assignment after birth | p-value | |||
β-carotene | Placebo | Vitamin A | ||
Sample size for males | ||||
Subjects n | 254 | 202 | 226 | |
Subjects per ward | 25 (14–44) | 22 (9–45) | 19 (5–70) | 0.71 |
FEV1/FVC for males | ||||
FEV1/FVC % | 87.5±7.1 | 87.6±6.1 | 87.8±6.0 | 0.88 |
FEV1/FVC % (mean of ward means) | 87.6±1.3 | 87.5±1.8 | 88.1±1.2 | 0.66 |
PEF for males | ||||
PEF L·s−1 | 3.66±0.91 | 3.78±0.82 | 3.79±0.75 | 0.17 |
PEF L·s−1 (mean of ward means) | 3.69±0.19 | 3.91±0.33 | 3.86±0.23 | 0.18 |
FEF75% for males | ||||
FEF75% L·s−1 | 0.86±0.34 | 0.83±0.30 | 0.89±0.33 | 0.15 |
FEF75% L·s−1 (mean of ward means) | 0.87±0.07 | 0.83±0.06 | 0.89±0.06 | 0.17 |
MMEF for males | ||||
MMEF L·s−1 | 1.93±0.59 | 1.92±0.52 | 1.98±0.53 | 0.44 |
MMEF L·s−1 (mean of ward means) | 1.94±0.13 | 1.95±0.13 | 2.01±0.14 | 0.52 |
Sample size for females | ||||
Subjects n | 209 | 217 | 214 | |
Subjects per ward | 22 (12–47) | 26 (7–45) | 19 (6–55) | 0.99 |
FEV1/FVC for females | ||||
FEV1/FVC % | 89.1±6.6 | 88.9±6.8 | 89.4±6.1 | 0.75 |
FEV1/FVC % (mean of ward means) | 89.0±2.2 | 88.7±1.6 | 89.4±2.2 | 0.75 |
PEF for females | ||||
PEF L·s−1 | 3.45±0.79 | 3.50±0.88 | 3.49±0.74 | 0.80 |
PEF L·s−1 (mean of ward means) | 3.44±0.30 | 3.61±0.47 | 3.47±0.19 | 0.55 |
FEF75% for females | ||||
FEF75% L·s−1 | 0.85±0.34 | 0.81±0.32 | 0.8±0.32 | 0.47 |
FEF75% L·s−1 (mean of ward means) | 0.84±0.12 | 0.84±0.13 | 0.86±0.12 | 0.90 |
MMEF for females | ||||
MMEF L·s−1 | 1.90±0.55 | 1.86±0.57 | 1.93±0.51 | 0.45 |
MMEF L·s−1 (mean of ward means) | 1.89±0.21 | 1.90±0.23 | 1.93±0.16 | 0.92 |
Data are presented as median (range) or mean±sd, unless otherwise stated. FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; PEF: peak expiratory flow; FEF75%: forced expiratory flow at 75% of FVC; MMEF: maximum mid-expiratory flow.